• Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

(970) 818-8343

info@cetya-therapeutics.com
Cetya TherapeuticsCetya Therapeutics
  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

News & Publications

News

Cetya Therapeutics welcomes Dr. Anthony Wutoh to its Board of Directors

Provost & Chief Academic Officer of Howard University brings scientific experience and new perspectives on…

June 21, 2022Read More

Cetya Therapeutics Appoints Ron Lowy to Board of Directors

Adds extensive life science senior experience and transactional capability to the Board of Directors Fort…

July 1, 2020Read More

Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102

Drug candidate active against EGFR and KRAS mutant lung cancer cell lines Fort Collins, CO,…

June 11, 2020Read More
Photo by Science in HD on Unsplash

Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors

Novel Chemistry Allows Conjugation of Largazole Analogs to Receptor Ligands or Other Cytotoxic Agents Fort…

January 29, 2020Read More

Cetya Therapeutics Announces Phase II STTR Grant Award

 $1,000,000 NIH Grant will further development of Cetya’s HDAC inhibitor CT-101 for treatment of sickle…

September 23, 2019Read More

Cetya Therapeutics announces advanced industries award

$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.

December 1, 2017Read More

Cetya Therapeutics announces STTR grant

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.

September 22, 2017Read More

Cetya Therapeutics announces seed round financing

$220,000 Round includes Canadian firm InSynchrony Ventures Inc Proceeds will advance oncology drug development. Fort…

May 8, 2017Read More

Publications

  1. Bowers, A.; West, N.; Taunton, J.; Schreiber, S. L.; Bradner, J. E.; and R. M. Williams, Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor. J Am Chem Soc. 2008, 130, 11219–22. >>
  2. Guerra-Bubb, J. M.; Bowers, A.; Smith, W. B.; Paranal, R.; Estiu, G.; Wiest, O.; Bradner, J. E.; and R. M. Williams, Synthesis and HDAC Inhibitory Activity of Isosteric Thiazoline-Oxazole Largazole Analogs. Bioorg. Med. Chem. Lett. 2013, 23, 6025–8. >>
  3. Bowers, A. A.; West, N.; Newkirk, T. L.; Troutman-youngman, A. E.; Schreiber, S. L.; Wiest, O.; Bradner, J. E.; and R. M. Williams, Synthesis and HDAC Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold. Org Lett. 2009, 11, 1301–1304. >>
  4. Bowers, A. A.; Greshock, T. J.; West, N.; Estiu, G.; Stuart, L.; Wiest, O.; Williams, R. M.; and J. E. Bradner, Synthesis and Conformation-Activity Relationships of the Peptide Isosteres of FK228 and Largazole. J Am Chem Soc. 2009, 131, 2900–2905. >>
  5. Pilon J.L., Clausen D.J., Hansen R.J., Lunghofer P.J., Charles B., Rose B.J., Thamm D.H., Gustafson D.L., Bradner J.E., Williams R.M. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi largazole and largazole peptide isostere. Cancer Chemother. Pharmacol. 2015;75:671–682. doi: 10.1007/s00280-015-2675-1. >>
  6. Junker L.H., Li B., Zhu X., Koti S., Cerbone R.E., Hendrick C.L., Sangerman J., Perrine S., Pace B.S. Novel histone deacetylase inhibitor CT-101 induces γ-globin gene expression in sickle erythroid progenitors with targeted epigenetic effects. Blood Cells Mol. Dis. 2021; 93:102626. doi.org/10.1016/j.bcmd.2021.102626. >>

HDACIs with best-in-class potency and isoform selective drug candidates

Learn More

Contact Us

We're currently offline. Send us an email and we'll get back to you, asap.

Send Message

Menu

  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

Contact

  • (303) 895-8216
  • info@cetya-therapeutics.com
Cetya Therapeutics, Inc.

320 E Vine Drive, Suite 128
Fort Collins, CO 80524

© 2018 · Cetya Therapeutics